Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Tampa, FL
NPI: 1063733343Primary Employer
Moffitt Medical Group
moffitt.org
HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2013 - 2027
MA State Medical License
2012 - 2015
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
USF Health Morsani College of Medicine
health.usf.edu
Medical School
Until 2010
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General Hospital
Fellowship • Hematology and Medical Oncology
2013 - 2016
Mass General Brigham/Massachusetts General Hospital
Residency • Internal Medicine
2010 - 2013
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 80 | 102 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 70 | 101 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 55 | 55 |
Authors: Andrew Kuykendall, Jeffrey Lancet, Kendra Sweet, Onyee Chan, Rami Komrokji, Eric Padron
Journal: Haematologica
Publication Date: 2023-04-01
Authors: Stephen Nimer, Rafael Bejar, Olatoyosi Odenike, Jan Philipp Bewersdorf, Gail Roboz, Hetty Carraway, Andrew Brunner, Mikkael Sekeres, Stephanie Halene, Amy Dezern, Amer Zeidan, Zhuoer Xie, Eric Padron, Alan List, Peter Greenberg, Naval Daver
Journal: Leukemia
Publication Date: 2022-10-20
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Darbepoetin Alfa, DRUG: Canakinumab Injection
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Intervention / Treatment: BIOLOGICAL: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, DRUG: Standard of Care Chemotherapy
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: National Institute of Nursing Research (NINR)